Back to results
US 8,754,045 B2Granted
Enzymatic debridement therapy for abnormal cell proliferation
OwnerJames A. Livingstoninventor
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.
Claims16
A method of treating a cancer in a patient, comprising administering to a patient in need thereof a treatment effective amount of a composition consisting of one or more debridement enzymes and one or more denaturants, and a pharmaceutically acceptable carrier, wherein the cancer is a leukemia, ovarian, breast, colon, prostate, lung, renal, or CNS cancer.
Dependencies are inferred from the claim text.